Study guide
17.2 Root Cause Analysis and CAPA Design
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
17.2 Root Cause Analysis and CAPA Design
Key Takeaways Explain This Topic AI
Root-cause analysis tests underlying causes rather than accepting an unsupported blame statement.
Correction addresses an existing problem; corrective action addresses its cause.
Preventive action addresses causes of potential future nonconformity.
Last updated: October 2026
Root Cause Analysis and CAPA Design
Problem Statement: Subject 204 received a 300 mg dose of investigational oncology drug instead of the protocol-mandated 200 mg dose under the protocol's weight-band dose table.
Why #1: Why did the subject receive 300 mg? Because the research pharmacist prepared the infusion bag using a wrong weight-band category copied from an outdated worksheet rather than the current protocol dose table.
Why #2: Why did the pharmacist use an incorrect weight-band category? Because the prescription worksheet provided by the study coordinator listed an outdated weight from a prior screening visit conducted two months earlier.
Why #3: Why did the coordinator record an outdated weight on the prescription worksheet? Because the clinical electronic health record (EHR) contains multiple conflicting weight entries across inpatient and outpatient modules, and the coordinator selected the top entry without cross-referencing day-of-dosing vitals.
Why #4: Why did the coordinator not confirm the day-of-dosing weight? Because the site clinic has no standardized chemotherapy order verification checklist requiring concurrent verification of day-of-treatment vitals before transmitting orders to pharmacy.
Why #5 (Root Cause): The investigative site lacks an institutional Standard Operating Procedure (SOP) and dual-signature verification process governing investigational chemotherapy order transcription and pharmacy communication.
If the CRA had accepted the superficial explanation ( "the coordinator made a clerical mistake; coordinator was verbally retrained" ), the lack of an order verification process would inevitably lead to another dosing error when a different coordinator or pharmacist handled a subject.
The Ishikawa (Fishbone) Diagram
The Ishikawa diagram (also termed the cause-and-effect or fishbone diagram) provides a structured graphical framework for categorizing potential contributors to a complex failure. In clinical trial operations, causes are evaluated across six core operational domains:
People: Personnel qualifications, lack of protocol-specific training, clinical coordinator turnover, investigator absence, staff fatigue, or language barriers.
Process: Ambiguous site SOPs, overly restrictive protocol visit windows, lack of standardized worksheets, absent secondary verification steps, or cumbersome subject appointment handoffs.
Equipment: Uncalibrated infusion pumps, freezer temperature excursions, broken centrifuges, malfunctioning ECG machines, or software access lockouts.
Materials: Damaged central laboratory kits, expired collection tubes, ambiguous drug labeling, or missing investigational drug reconstitution diluents.
Environment: Clinic room overcrowding, power outages, excessive ambient room temperature affecting drug stability, or courier delivery disruptions.
Management / Governance: Inadequate Principal Investigator oversight, insufficient research coordinator staffing allocations, conflicting institutional priorities, or poor communication between clinic and research pharmacy.
Pareto Analysis (The 80/20 Rule)
Pareto analysis ranks categories by observed frequency or impact. The familiar 80/20 pattern is a heuristic, not an established rate for clinical trials. When auditing site compliance across a multi-center study, a CRA or central monitor aggregates all recorded deviations (e.g., missed visits, out-of-window labs, unrecorded concomitant medications). By categorizing and plotting deviations on a Pareto chart, the study team can identify the "vital few" operational bottlenecks (such as an overly complex 15-minute PK sampling window) versus the "trivial many" isolated mistakes.
Developing Effective Corrective and Preventive Action (CAPA) Plans
A critical failure mode in clinical research administration is the submission of vague, un-enforceable CAPA plans that fail to satisfy regulatory muster. Global health authorities (FDA, EMA, MHRA) routinely issue inspection findings for superficial CAPAs that state nothing more than "retrained staff on the protocol."
The Three Tiers of Remediation
To construct a well-supported CAPA, the CRA and investigative site must clearly differentiate between three distinct operational levels:
Correction (Immediate Remediation / Containment):
What action was executed immediately to contain the damage and resolve the isolated error?
Focuses strictly on the immediate subject, sample, or data point affected.
Examples: Administering a reversal agent or rescue therapy to an overdosed participant; obtaining emergency re-consent on the current IRB-approved form; quarantining suspect vials in an excursion-affected freezer; recalling a mislabeled specimen.
Corrective Action (Root Cause Elimination at the Site):
What permanent action will eliminate the identified root cause to prevent recurrence of that specific failure mode at the investigative site?
Focuses on modifying site procedures, tools, workflows, or oversight structures.
Examples: Revising the site's chemotherapy prescription workflow to mandate dual independent RN/PharmD calculation checks; reconfiguring the electronic scheduling software to lock appointments outside the allowable ±2-day protocol window; replacing an outdated laboratory requisition template with an automated pre-populated barcode system.
Preventive Action (Systemic Proactive Mitigation Across the Organization):
What proactive action will eliminate the root cause of potential non-compliance across other clinical trials, other investigative sites, or future research programs before errors occur?
Focuses on enterprise-wide, institutional, or sponsor-wide quality improvement.
Examples: The sponsor updating the master protocol template across an entire clinical development program to widen impractical visit windows; the academic medical center implementing a mandatory research credentialing policy for all clinical department chairs; updating the institutional CTMS to flag conflicting clinical trial appointments hospital-wide.
Applying SMART Criteria to CAPA Design
The SMART framework is a useful planning method, not an ICH-mandated acronym. Well-defined action items are:
Specific: Defines precisely what operational action will be taken, which role is responsible, and which process is modified.
Measurable: Establishes objective, quantifiable performance indicators to evaluate whether the intervention achieved its goal.
Achievable: Operationally realistic given the site's staffing, technology infrastructure, and clinical resources.
Relevant: Directly addresses the confirmed root cause identified during RCA, rather than an unrelated administrative symptom.
Time-bound: Designates exact calendar deadlines for implementation, staff training, and subsequent effectiveness evaluations.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .